ImmunityBio Directors Sold $3.9M Before Earnings Miss
Three ImmunityBio directors completed $3.92 million in open-market share sales between June 4 and July 2, before an August 4 earnings report that disclosed a 175% EPS miss, the worst shortfall in four
ImmunityBio Directors Cleared $3.9M Above Market Before a 175% EPS Miss
NEW YORK, August 16, ImmunityBio, Inc. (IBRX) is heading for its best weekly gain since February on anticipation of Anktiva and BCG data due the week of August 23. What the rally buries: three directors completed $3.92 million in open-market share sales at $7.18 to $9.50 between June 4 and July 2, none disclosed as 10b5-1 pre-scheduled trades, weeks before the August 4 earnings report that disclosed a 175% EPS miss, the worst shortfall in four quarters.
Five of Six Sale Tranches Were Priced Above Today's Market
Director Christobel Selecky sold 256,200 shares across three transactions between June 29 and July 2, receiving approximately $2.31 million at $9.00 to $9.02. Director Cheryl Cohen sold 131,210 shares at $9.50 on July 2 for $1.25 million, simultaneously exercising options at $2.98. Director Barry Simon's June 4 sale at $7.18 is the only tranche priced below the current $7.57; the other five cleared above where the stock trades today. Because these are characterized as open-market sales with no 10b5-1 plan designation in the filings, they are discretionary transactions, not pre-scheduled sells insulated from timing questions, executed in the eight weeks before the company reported Q2 EPS of -$0.22 against consensus.
99.3% Gross Margin Cannot Offset a $281M Annual Cash Burn
Anktiva, the FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer, has generated $170 million in trailing revenue growing 94% year-over-year at a 99.3% gross margin, a commercial profile that would be enviable at any stage of biotech development. The balance sheet runs the other direction: $1.23 billion in total debt against $360 million in cash, with operating cash flow of -$281 million over the trailing twelve months. An $8 billion market cap against that burn rate prices in substantial pipeline expansion beyond the current NMIBC approval, expansion the founder's announcement of a new Anktiva-NK cell therapy combination study is designed to validate. Short interest at 32.2% of float reflects exactly that pricing gap.
HOW IBRX STACKS UP, data at publish
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IBRX | $8.0B | n/a | +211.5% |
| IOVA | $3.2B | n/a | +179.2% |
| SMMT | $10.6B | n/a | -49.2% |
| RXRX | $1.7B | n/a | -42.8% |
| SLS | $2.6B | n/a | +638.7% |
| BBIO | $15.6B | 215.7x | +62.9% |
The August 23 Readout Settles the Valuation, Not the Director Sales
A consensus analyst target of $12.75, a 68% premium to $7.57, and 32.2% short interest are the same binary bet from opposite sides. The pre-earnings director sales, absent 10b5-1 protections, added $3.92 million of selling pressure at prices the stock has since failed to reclaim on five of six tranches; that is the signal, not a hedge. The number that renders the director timing irrelevant or damning is the August 23 Anktiva data: a clean readout closes the gap toward $12.75 and collapses the short thesis; a miss leaves an $8 billion market cap resting on $170 million in revenue against $281 million in annual cash burn, with no 10b5-1 plan language to contextualize why three insiders sold above market in the weeks prior.
Run the free ImmunityBio, Inc. deep-dive → for the latest numbers.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
ImmunityBio stock is heading for its best weekly gain since February as the company prepares to unveil fresh Anktiva and BCG data next week — yet the same company just posted its worst earnings miss in four quarters and carries $1.23 billion in debt against $360 million in cash.